BIOMARIN PHARMACEUTICAL INC - NOTE 1.500%10/1 Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2020

Type / Class
Debt / NOTE 1.500%10/1
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of BIOMARIN PHARMACEUTICAL INC - NOTE 1.500%10/1 across Reporting Periods

Period Principal Value Change Price (% of par) (Median) Investors
2020 Q4 $0 $0 -$356,597,732 0
2020 Q3 $357,830,003 $356,597,732 +$39,494,990 100.0% 31
2020 Q2 $300,962,722 $403,720,012 +$10,712,324 131.64% 36
2020 Q1 $308,997,716 $327,784,733 -$69,719,766 106.01% 43
2019 Q4 $376,224,752 $408,859,034 +$23,268,637 108.49% 42
2019 Q3 $355,672,715 $367,172,767 +$12,660,645 103.03% 42
2019 Q2 $338,310,775 $380,676,320 +$29,874,539 112.35% 40
2019 Q1 $311,697,275 $355,084,750 -$5,417,364 113.73% 36
2018 Q4 $313,848,215 $349,728,786 +$2,820,486 111.49% 36
2018 Q3 $309,548,014 $371,510,616 +$15,678,767 120.0% 39
2018 Q2 $296,728,014 $350,176,017 -$5,722,720 118.46% 39
2018 Q1 $301,833,012 $333,583,633 -$10,537,705 110.4% 38
2017 Q4 $307,516,012 $365,262,609 +$35,523,840 118.71% 38
2017 Q3 $277,558,000 $333,526,332 -$62,666,508 120.0% 38
2017 Q2 $333,374,000 $396,972,968 -$7,996,093 119.1% 38
2017 Q1 $340,001,000 $402,506,343 +$1,086,887 118.22% 40
2016 Q4 $339,236,012 $399,582,215 +$28,890,823 117.69% 39
2016 Q3 $313,097,012 $391,105,519 +$16,672,390 124.7% 41
2016 Q2 $300,529,013 $347,575,209 +$10,238,101 115.62% 41
2016 Q1 $291,502,000 $346,586,311 +$24,083,150 118.58% 42
2015 Q4 $271,082,500 $363,534,359 -$19,897,266 133.79% 41
2015 Q3 $285,934,000 $385,434,373 -$18,978,023 134.38% 40
2015 Q2 $281,956,524 $449,251,630 -$19,201,721 159.25% 41
2015 Q1 $299,622,500 $453,698,776 -$74,212,981 151.43% 42
2014 Q4 $354,131,567 $433,715,692 -$23,247,766 122.56% 38
2014 Q3 $375,079,000 $412,240,000 +$20,778,923 109.5% 40
2014 Q2 $352,192,000 $372,338,000 +$32,130,318 105.31% 35
2014 Q1 $324,994,000 $361,571,000 +$20,261,074 111.0% 37